Could a common circulation drug stop strokes before they strike again?
NCT ID NCT07174414
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether adding cilostazol, a drug that improves blood flow, to standard aspirin or clopidogrel therapy can prevent another stroke or heart attack in people who have recently had a stroke or mini-stroke. About 2,000 participants will take either cilostazol or a placebo twice daily for several years. The goal is to see if the combination reduces major cardiovascular events like stroke, heart attack, or vascular death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cilostazol
What this could lead to
If it works, this could provide a new, affordable way to reduce the risk of another stroke or heart attack in people who have already had one.
What could go wrong
This is a large phase 3 trial, but cilostazol may not reduce events more than placebo, and it carries risks like bleeding or heart-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Stanford, California, 94305, United States